Cwm LLC Sells 530 Shares of Glaukos Co. (NYSE:GKOS)

Cwm LLC lowered its stake in shares of Glaukos Co. (NYSE:GKOS) by 38.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 854 shares of the medical instruments supplier’s stock after selling 530 shares during the quarter. Cwm LLC’s holdings in Glaukos were worth $68,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GKOS. Invesco Ltd. lifted its holdings in shares of Glaukos by 45.5% during the 3rd quarter. Invesco Ltd. now owns 1,450,033 shares of the medical instruments supplier’s stock valued at $109,115,000 after purchasing an additional 453,756 shares during the last quarter. Rhenman & Partners Asset Management AB raised its stake in Glaukos by 236.8% in the third quarter. Rhenman & Partners Asset Management AB now owns 320,000 shares of the medical instruments supplier’s stock valued at $24,080,000 after buying an additional 225,000 shares during the last quarter. Fred Alger Management LLC boosted its holdings in Glaukos by 9.2% in the third quarter. Fred Alger Management LLC now owns 1,780,690 shares of the medical instruments supplier’s stock worth $133,997,000 after acquiring an additional 150,102 shares in the last quarter. Lisanti Capital Growth LLC acquired a new position in shares of Glaukos during the third quarter valued at about $6,367,000. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Glaukos by 3,894.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 72,978 shares of the medical instruments supplier’s stock valued at $5,801,000 after purchasing an additional 71,151 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 1,512 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $96.80, for a total value of $146,361.60. Following the sale, the chief operating officer now directly owns 119,802 shares of the company’s stock, valued at $11,596,833.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Glaukos news, COO Joseph E. Gilliam sold 1,512 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $96.80, for a total transaction of $146,361.60. Following the completion of the transaction, the chief operating officer now directly owns 119,802 shares in the company, valued at $11,596,833.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Alex R. Thurman sold 434 shares of Glaukos stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $95.33, for a total transaction of $41,373.22. Following the completion of the sale, the chief financial officer now owns 54,166 shares in the company, valued at approximately $5,163,644.78. The disclosure for this sale can be found here. Insiders sold a total of 230,544 shares of company stock worth $21,767,497 in the last 90 days. Corporate insiders own 6.40% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. BTIG Research boosted their target price on shares of Glaukos from $107.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Citigroup upped their target price on Glaukos from $107.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 25th. Jefferies Financial Group raised Glaukos from a “hold” rating to a “buy” rating and lifted their price target for the stock from $84.00 to $125.00 in a research report on Monday. Stifel Nicolaus reaffirmed a “buy” rating and set a $110.00 target price on shares of Glaukos in a report on Wednesday, April 3rd. Finally, JPMorgan Chase & Co. increased their price target on shares of Glaukos from $108.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and a consensus price target of $108.64.

Glaukos Price Performance

Shares of NYSE GKOS opened at $106.91 on Thursday. The company has a debt-to-equity ratio of 0.78, a current ratio of 5.38 and a quick ratio of 4.68. The firm’s 50 day simple moving average is $94.28 and its 200-day simple moving average is $83.79. Glaukos Co. has a 12 month low of $54.38 and a 12 month high of $110.73. The stock has a market capitalization of $5.38 billion, a price-to-earnings ratio of -37.12 and a beta of 1.08.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.12). Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The firm had revenue of $85.60 million for the quarter, compared to analyst estimates of $79.60 million. During the same quarter in the prior year, the business posted ($0.59) EPS. The firm’s quarterly revenue was up 15.8% compared to the same quarter last year. Analysts expect that Glaukos Co. will post -2.2 EPS for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.